Please login to the form below

Not currently logged in
Email:
Password:

Agreement to develop depression treatment

Marco Polo Pharmaceuticals and Biocortech are to develop BC-19 in treatment-resistant depression

Luxembourg-based Marco Polo Pharmaceuticals, has entered into a licensing agreement with French diagnostics company, Biocortech, to develop BC-19 in treatment-resistant depression. Under the terms of the agreement, Marco Polo takes responsibility for all further clinical development of BC-19 and for eventual commercialisation or outlicensing to a suitable partner.

BC-19 is an eburnamine derivative, previously investigated for the indications of cerebral insufficiency and cognitive deficits. As an antidepressant, it showed benefits when administered to patients suffering from treatment-resistant depression.

Moreover, BC19 offers the possibility of disease modification by restoring the function of deficient noradrenergic pathways, which terminate in the prefrontal cortex.

"It is a great accomplishment for our company to announce a licensing agreement of this kind," said Prof Mondher Toumi, CEO of Marco Polo Pharmaceuticals.

The company's chief medical officer, Dr Aleksandar Bakhutshuili, added: "There is a major unmet need in resistant and melancholic depression, and we believe that this compound will help those who suffer from this disease. Our team looks forward to further developing BC-19 in these indications."

"This agreement, which is aligned with our strategic shift toward biomarkers, is a great opportunity to move BC-19 development forward and to bring a novel class of promising compounds to patients," said Dr Dinah Weissmann, CEO of Biocortech.

Treatment-resistant depression is a common manifestation of major depressive disorder, where patients do not respond to adequate courses of at least two different antidepressants. It is estimated that 10-30 per cent of cases are either partially or totally resistant to antidepressant therapy.

Marco Polo Pharmaceuticals is a drug repositioning company that identifies, acquires and develops promising drug candidates in new indications or markets. It focuses on major central nervous system diseases.

Biocortech is a biopharmaceutical company working to discover and develop novel biomarkers for psychiatric disorders.

6th April 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics